Technical Analysis for CCXI - ChemoCentryx, Inc.

Grade Last Price % Change Price Change
grade A 44.18 -4.06% -1.87
CCXI closed down 4.06 percent on Thursday, February 27, 2020, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical CCXI trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Strong but Oversold Other 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish -4.06%
1,2,3 Pullback Bullish Bullish Swing Setup -4.06%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -4.06%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. Its drug candidates under clinical stage include Vercirnon, which is in Phase III clinical trials for the treatment of patients with moderate-to-severe Crohn's disease; CCX140 that is in Phase II clinical trials for the treatment of patients with diabetic nephropathy, a form of kidney disease; and CCX354 that completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis. The company's drug candidates also comprise CCX168, which is in a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody associated vasculitis; CCX872 that is under Phase I clinical development targeting CCR2 for expanded indications of renal disease; and CCX507, a de novo wholly-owned CCR9 inhibitor, which is in Phase I clinical trials for inflammatory bowel disease and related disorders. Its preclinical stage programs comprise CCX650, an orally active drug for the treatment of glioblastoma multiforme; CCR4 inhibitor for atopic dermatitis; CCX6239, an orally administered CCR4 antagonist with potential utility in the treatment of atopic dermatitis, an inflammatory disease; CCR6 inhibitor for autoimmune diseases; and CXCR6 inhibitor for chronic hepatitis. ChemoCentryx, Inc. has a strategic alliance with Glaxo Group Limited for the discovery and development of small molecule antagonists targeting four defined chemokine and chemo-attractant receptor targets and for advancing them through clinical proof-of-concept. The company was founded in 1997 and is headquartered in Mountain View, California.
Medicine Biopharmaceutical Cancer Immunology Autoimmune Diseases Monoclonal Antibodies Rheumatoid Arthritis Inflammatory Bowel Disease Atopic Dermatitis Immunosuppressants Diabetic Nephropathy Dermatitis Kidney Disease Biotie Therapies Glioblastoma Multiforme Inflammatory Disorders Janus Kinase Inhibitor Inflammatory Disease

Is CCXI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 51.36
52 Week Low 6.16
Average Volume 599,867
200-Day Moving Average 18.11
50-Day Moving Average 41.60
20-Day Moving Average 47.05
10-Day Moving Average 47.87
Average True Range 2.13
ADX 31.23
+DI 23.25
-DI 28.22
Chandelier Exit (Long, 3 ATRs ) 44.96
Chandelier Exit (Short, 3 ATRs ) 46.06
Upper Bollinger Band 52.08
Lower Bollinger Band 42.02
Percent B (%b) 0.21
BandWidth 21.37
MACD Line 1.67
MACD Signal Line 2.56
MACD Histogram -0.8854
Fundamentals Value
Market Cap 2.15 Billion
Num Shares 48.7 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -71.26
Price-to-Sales 12.42
Price-to-Book 7.97
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 49.37
Resistance 3 (R3) 49.45 47.80 48.51
Resistance 2 (R2) 47.80 46.48 47.76 48.22
Resistance 1 (R1) 45.99 45.66 45.17 45.91 47.93
Pivot Point 44.34 44.34 43.93 44.30 44.34
Support 1 (S1) 42.53 43.02 41.71 42.45 40.43
Support 2 (S2) 40.88 42.20 40.84 40.14
Support 3 (S3) 39.07 40.88 39.86
Support 4 (S4) 38.99